Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children.
About 4-10% of children and adolescents suffer from migraine. In the last few years, several studies have been performed to assess the efficacy and safety of triptans for the acute treatment of migraine in children and adolescents. Only sumatriptan nasal spray has been approved for the treatment of acute migraine with or without aura in adolescents aged 12-17 years in Europe. This review describes the results of the studies with sumatriptan nasal spray that have been performed in children and adolescents, including a study performed in the Netherlands.
Callenbach
Petra M C
PM
Department of Neurology, University Medical Centre Groningen, University of Groningen, P.O. Box 30 001 9700 RB Groningen, The Netherlands. p.m.c.tijink@neuro.umcg.nl
Pels
Lise P M
LP
Mulder
Paul G H
PG
Linssen
Wim H J P
WH
Gooskens
Rob H J M
RH
van der Zwan
Jan L
JL
Brouwer
Oebele F
OF
D000281:Administration, Intranasal; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage*; D018170:Sumatriptan / Q000008:administration & dosage*
D017366:Serotonin Receptor Agonists; D018170:Sumatriptan